Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain ACRS message board posts where the ticker symbol ACRS has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest ACRS SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, items 1.01, 2.02, 2.03, and 9.01
Acc-no: 0001558370-18-007692 (34 Act)  Size: 78 KB
2018-10-15 001-37581
181122379
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-054397 Size: 6 KB
2018-10-05
8-K  Documents Current report, item 1.02
Acc-no: 0001558370-18-007636 (34 Act)  Size: 25 KB
2018-10-04 001-37581
181108407
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001209191-18-050505 Size: 9 KB
2018-09-11
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-18-007612 (34 Act)  Size: 17 KB
2018-09-04 001-37581
181051545
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-048503 Size: 5 KB
2018-08-27
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-047417 Size: 6 KB
2018-08-17
D/A  Documents [Amend] Notice of Exempt Offering of Securities, item 06b
Acc-no: 0001192482-18-000391 (33 Act)  Size: 15 KB
2018-08-13 021-292766
181011821
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001558370-18-006295 (34 Act)  Size: 8 MB
2018-08-03 001-37581
18990369
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001558370-18-006287 (34 Act)  Size: 225 KB
2018-08-03 001-37581
18990296
More ACRS SEC Filings


Related news from
Tue, 16 Oct 2018
17:23:36 +0000
Edited Transcript of ACRS earnings conference call or presentation 15-Oct-18 9:00pm GMT
Q3 2018 Aclaris Therapeutics Inc Earnings Call
Tue, 16 Oct 2018
15:52:12 +0000
$65 million deal: Aclaris buying rights to rosacea drug from Allergan
Aclaris has entered into a deal for the rights to a rosacea treatment its senior managers helped develop while at the helm of a different Chester County biopharmaceutical company.
Mon, 15 Oct 2018
20:01:00 +0000
Aclaris Therapeutics to Acquire Worldwide Rights to RHOFADE® from Allergan
Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet patient needs in aesthetic and medical dermatology and immunology, today announced it has entered into a definitive asset purchase agreement with Allergan Sales, LLC to acquire worldwide rights to RHOFADE® (oxymetazoline hydrochloride) cream, 1% and additional intellectual property. The acquisition includes an exclusive license to certain intellectual property for RHOFADE, which is approved for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults.
Wed, 10 Oct 2018
18:42:24 +0000
Consolidated Research: 2018 Summary Expectations for Five Prime Therapeutics, National Health Investors, Starwood Property Trust, Inc., Biohaven Pharmaceutical Holding, Aclaris Therapeutics, and Mitek — Fundamental Analysis, Key Performance Indications
NEW YORK, Oct. 10, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Wed, 03 Oct 2018
11:00:00 +0000
Aclaris Therapeutics Announces Poster Presentations at 2018 American Society for Dermatologic Surgery Annual Meeting and Fall Clinical Dermatology Conference
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced poster presentations at the 2018 American Society for Dermatologic Surgery Annual Meeting in Phoenix, Arizona and the Fall Clinical Dermatology Conference in Las Vegas, Nevada. One poster is related to ESKATA® (hydrogen peroxide) topical solution, 40% (w/w), formerly known as “A-101,” and two posters examine the impact of seborrheic keratoses (SKs) on patients and the need to improve communication between dermatologists/HCPs on SK treatment options.
Tue, 02 Oct 2018
11:00:00 +0000
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WAYNE, Pa., Oct. 02, 2018 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing.
Mon, 01 Oct 2018
20:01:00 +0000
Aclaris Therapeutics Launches Direct-to-Consumer Campaign for ESKATA® (hydrogen peroxide) Topical Solution 40%, (w/w)
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced the launch of a direct-to-consumer campaign for ESKATA® (hydrogen peroxide) topical solution 40%, (w/w), the first and only FDA-approved topical treatment for raised seborrheic keratoses (SKs). The consumer awareness campaign is based on research that revealed that SKs can have an impact on our target audience.
Mon, 01 Oct 2018
17:25:39 +0000
Aclaris partnership with St. Louis university targets aspiring scientists from underrepresented minority groups
Aclaris Therapeutics will offer paid internship programs to up to two "high potential" Harris-Stowe State University students under the partnership. Future employment as associate scientists with the company is a possibility.
Mon, 01 Oct 2018
11:00:00 +0000
Aclaris Therapeutics Announces Partnership with Harris-Stowe State University to Support Development of Scientists from Underrepresented Minority Groups
WAYNE, Pa., Oct. 01, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant ...
Mon, 24 Sep 2018
11:00:00 +0000
Aclaris Therapeutics Announces First Patient Dosed in Phase 3 Studies Evaluating A-101 45% in Patients with Common Warts
Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced the initiation of a Phase 3 wart program evaluating A-101 (hydrogen peroxide) topical solution 45% (A-101 45%) in patients with common warts. “Common warts are a ubiquitous dermatological complaint and a frequent reason for physician visits.  These lesions can be persistent, irritating, uncomfortable, and are associated with a social stigma,” said Dr. David Gordon, Chief Medical Officer of Aclaris.
Fri, 21 Sep 2018
11:00:00 +0000
Aclaris Therapeutics to Attend Upcoming Investor Conferences
WAYNE, Pa., Sept. 21, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant ...
Mon, 17 Sep 2018
11:00:00 +0000
Aclaris Therapeutics to Highlight Drug Discovery Targeting the Human Kinome at 16th Annual Discovery on Target Meeting
WAYNE, Pa., Sept. 17, 2018-- Aclaris Therapeutics, Inc. announced that its subsidiary, Confluence Discovery Technologies, Inc., will present two posters at Cambridge Healthtech Institute’ s Discovery on ...
Tue, 21 Aug 2018
11:00:00 +0000
Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in the Journal Cancer Research
Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced a publication in the journal Cancer Research. ATI-450, an investigational drug, is a selective inhibitor of p38 mitogen-activated protein kinase-activated protein kinase 2 (p38MAPK/MK2) interface and an attractive candidate for stromal-targeted therapy. Levels of p38MAPKα expressed by a tumor and the surrounding stromal cells correlate with poor prognosis.
Thu, 16 Aug 2018
11:40:00 +0000
Edited Transcript of ACRS earnings conference call or presentation 3-Aug-18 12:00pm GMT
Q2 2018 Aclaris Therapeutics Inc Earnings Call
Fri, 03 Aug 2018
13:25:01 +0000
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of -6.32% and 33.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Fri, 03 Aug 2018
11:15:48 +0000
Aclaris: 2Q Earnings Snapshot
The Wayne, Pennsylvania-based company said it had a loss of $1.01 per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Fri, 03 Aug 2018
11:00:00 +0000
Aclaris Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments
Management to Host Conference Call at 8:00 AM ET today. WAYNE, Pa., Aug. 03, 2018-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing ...
Fri, 03 Aug 2018
10:00:00 +0000
Aclaris Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 3, 2018 / Aclaris Therapeutics, Inc. (NASDAQ: ACRS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 3, 2018 at 8:00 AM Eastern ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum has meant the difference between mediocre and stellar stock performance, peace of mind about retirement and meeting and making wonderful friends. VF is simply the BEST." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards